Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
Recurrent and multiple bladder tumors show conserved expression profiles.
PMID 18590527 · PMC2483988 · BMC cancer · 2008 · 8 claims · 7 setups
Recurrent and multiple bladder tumors from the same patient display remarkably similar gene expression profiles despite genomic differences.
-
Has reproduction · 66
Prime editing in mice reveals the essentiality of a single base in driving tissue-specific gene expression.
PMID 33722289 · PMC7962346 · Genome biology · 2021 · 7 claims · 8 setups
A three-base-pair (HDR) or single-base (PE2) substitution in the Tspan2 CArG box causes cell-specific loss of Tspan2 mRNA in aorta and bladder, but not heart or brain
-
Full-text index only
Uropathogenic Escherichia coli invade luminal prostate cells via FimH-PPAP receptor binding.
PMID 41507584 · PMC12872464 · Nature microbiology · 2026 · 8 claims · 8 setups
A 2D mouse stem cell-derived prostate epithelial organoid model was developed that mimics epithelial heterogeneity of the murine prostate
-
Full-text index only
[Research progress in SELDI-TOF MS and its clinical applications].
PMID 17168305 · PMC7148935 · Sheng wu gong cheng xue bao = Chinese journal of biotechnology · 2006 · 4 claims · 4 setups
Proteinchip profiling based on SELDI-TOF MS is a powerful and innovative proteomic technology for biomarker discovery and diagnostic/prognostic assay development.
-
Has reproduction · 64
Spatial-reprogramming derived GPNMB(+) macrophages interact with COL6A3(+) fibroblasts to enhance vascular fibrosis in glioblastoma.
PMID 41174767 · PMC12577258 · Genome medicine · 2025 · 8 claims · 8 setups
COL6A3+ TAFs are a distinct matrix-fibroblast subset significantly enriched in non-responders to neoadjuvant antiangiogenic+ICB combination therapy